161 results
8-K
EX-99.1
UTMD
Utah Medical Products, Inc.
25 Apr 24
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2024
2:59pm
the lower CSI IIA amortization expense in G&A expenses were $342 higher litigation expenses. Combining the changes in CSI IIA amortization … and litigation costs with other G&A expense increases, total consolidated G&A expenses were just $668 lower in 1Q 2024 than in 1Q 2023. The other components of OE
8-K
EX-99.1
UTMD
Utah Medical Products, Inc.
30 Jan 24
UTMD Reports Audited Year 2023 and Fourth Quarter Financial Performance
2:53pm
consistent with 2022, although the result was near its targeted 60% level for the year. OI margins were further diluted by unusual litigation expense … in litigation expense and in the amortization of the $21 million identifiable intangible asset (IIA) associated with UTMD’s 2019 purchase of CooperSurgical
8-K
EX-99.1
0rokj1chmx23mh1w07x7
26 Oct 23
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2023
3:30pm
8-K
EX-99.1
6wftqx eut8u
25 Jul 23
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2023
2:48pm
S-8
EX-10.6
4aithy3frvapjlaq9
14 Jul 23
Registration of securities for employees
4:55pm
8-K
EX-99.1
2qgsz vtm
25 Apr 23
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2023
4:01pm
8-K
EX-99.1
sthq93
25 Oct 22
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2022
2:48pm
8-K
EX-99.1
ophd ty1vguwnu40a
27 Jul 22
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2022
5:58pm